Keros Therapeutics, Inc.

KROS

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001664710

SEC filings (opens in a new tab)

In the last 90 days, Keros Therapeutics, Inc. insiders filed 2 open-market purchases and 4 sales; 132 institutions reported holding it in 13F filings for Q2 2026, worth $198.6M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Keros Therapeutics, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021 All holders in Q3 2021

13F holders of KROS: Q3 2021 compared with Q4 2021
Measure	Q3 2021	Of which not filed for Q4 2021	Q4 2021	Change
Holders	89	1	99	+11
Shares	13.8M	2.77K	16.2M	+2.36M (+17.1%)
Value	$545.4M	$110.0K	$944.5M	+$399.2M (+73.2%)

1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (26)

Institutions that held Keros Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to KROS in Q4 2021
Institution	Shares	Value	% of portfolio
Deep Track Capital, LP	1,300,000	$76.1M	5.62%
Octagon Capital Advisors LP	340,214	$19.9M	3.87%
Cormorant Asset Management, LP	150,000	$8.78M	0.52%
Sphera Funds Management Ltd.	119,681	$7.00M	0.83%
Darwin Global Management, Ltd.	111,500	$6.52M	1.00%
Parkman Healthcare Partners LLC	69,861	$4.09M	0.92%
Allianz Asset Management GmbH	47,847	$2.79M	0.00%
Integral Health Asset Management, LLC	35,000	$2.05M	0.57%
Wellington Management Group LLP	18,757	$1.10M	0.00%
Schonfeld Strategic Advisors LLC	16,044	$939.0K	0.01%
EDBI Pte Ltd	10,105	$591.0K	0.32%
UBS Asset Management Americas Inc	8,010	$468.7K	0.00%
Handelsbanken Fonder AB	7,400	$433.0K	0.00%
Price T Rowe Associates Inc	6,567	$384.0K	0.00%
Hyperion Capital Advisors LP	4,042	$236.0K	0.05%
Parametric Portfolio Associates LLC	3,981	$233.0K	0.00%
Arizona State Retirement System	3,455	$202.0K	0.00%
Ensign Peak Advisors, Inc	2,380	$139.0K	0.00%
Nisa Investment Advisors, LLC	860	$40.0K	0.00%
High Net Worth Advisory Group LLC	500	$29.0K	0.01%
Zullo Investment Group, Inc.	300	$18.0K	0.01%
Leonteq Securities AG	270	$15.8K	0.00%
Point72 Hong Kong Ltd	198	$12.0K	0.00%
Quantbot Technologies LP	200	$11.0K	0.00%
National Bank of Canada	30	$2.00K	0.00%
CWM, LLC	8	$0	0.00%

Sold out (15)

Institutions that held Keros Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of KROS in Q4 2021
Institution	Shares, Q3 2021	Value, Q3 2021
Avidity Partners Management LP	145,100	$5.74M
Norges Bank	52,700	$2.08M
Two Sigma Investments, LP	26,404	$1.04M
Hound Partners, LLC	25,000	$989.0K
Renaissance Technologies LLC	24,572	$972.0K
Two Sigma Advisers, LP	18,800	$744.0K
ExodusPoint Capital Management, LP	15,952	$631.0K
Logos Global Management LP	15,000	$593.0K
Affinity Asset Advisors, LLC	12,500	$495.0K
Silverarc Capital Management, LLC	10,000	$396.0K
Jefferies Group LLC	10,000	$395.6K
Ironsides Asset Advisors, LLC	6,456	$255.0K
Psagot Value Holdings Ltd. / (Israel)	2,772	$110.0K
Penserra Capital Management LLC	535	$21.0K
HighMark Wealth Management LLC	148	$3.00K

Not filed for Q4 2021 yet (1)

Institutions that held Keros Therapeutics, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding KROS in Q3 2021 that haven't filed for Q4 2021
Institution	Shares, Q3 2021	Value, Q3 2021
Psagot Investment House Ltd.	2,772	$110.0K